Long-term omalizumab use in the treatment of exercise-induced anaphylaxis

Allergy & Rhinology
Mark R Peterson, Christopher A Coop

Abstract

Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed. He was refractory to these medications and continued to have episodes of EIA. He was then started on a trial of omalizumab, an immunoglobulin E monoclonal antibody, and had resolution of the EIA episodes. After discontinuation of the omalizumab, the EIA episodes returned. He was restarted on omalizumab and since that time, has had 5 years free of EIA episodes and can now exercise without any symptoms. To our knowledge, this is only the third case in the literature of successful treatment of EIA by using omalizumab. This case was unique because it provided successful long-term use of omalizumab for EIA. Further studies are recommended for the use of omalizumab in the treatment of EIA.

References

Aug 1, 1984·The Journal of Allergy and Clinical Immunology·M D TharpT J Sullivan
May 1, 1984·The Journal of Allergy and Clinical Immunology·A L Sheffer, K F Austen
May 18, 1999·The Journal of Allergy and Clinical Immunology·K PalosuoT Reunala
Aug 8, 2001·International Archives of Allergy and Immunology·A RomanoP Zeppilli
May 8, 2007·The Journal of Allergy and Clinical Immunology·Melody C CarterDean D Metcalfe
Dec 6, 2008·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Jeremy D JonesJohn M Fahrenholz
Apr 10, 2009·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Priya Warrier, Thomas B Casale
Jun 15, 2010·Current Opinion in Allergy and Clinical Immunology·Paula Robson-Ansley, George Du Toit
Aug 3, 2010·The Journal of Allergy and Clinical Immunology·Hana M TartibiDavid A Khan
Oct 6, 2010·Current Allergy and Asthma Reports·Wojciech BargAnna Wolanczyk-Medrala
Sep 27, 2012·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Sarah M BrayAndrej A Petrov
Feb 17, 2015·Materia Socio-medica·Dukagjin ZogajMehmet Hoxha
Mar 20, 2015·PloS One·Denise LoizouOral Alpan
Aug 28, 2015·Journal of Pharmacology & Pharmacotherapeutics·Sapna GajbhiyePradeep Phadnis
Nov 15, 2016·The Journal of Allergy and Clinical Immunology. in Practice·Morten J Christensen, Carsten Bindslev-Jensen

❮ Previous
Next ❯

Citations

Mar 21, 2019·Current Opinion in Allergy and Clinical Immunology·Ru-Xin FoongGeorge du Toit
Jul 16, 2019·Expert Review of Clinical Immunology·Filipe Benito-GarciaMário Morais-Almeida
Apr 28, 2019·Current Allergy and Asthma Reports·Elise CoulsonCem Akin
May 8, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·G J MolderingsL B Afrin
Oct 28, 2018·Current Allergy and Asthma Reports·Matthew P Giannetti

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Related Papers

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
Sarah M BrayAndrej A Petrov
The Journal of Allergy and Clinical Immunology. in Practice
Morten J Christensen, Carsten Bindslev-Jensen
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
James P Rosen
The Journal of the Kansas Medical Society
J M Shields, N S Nowlin
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
Troy W BakerThomas L Johnson
© 2022 Meta ULC. All rights reserved